0107 Werewolf series B
BioCentury & Getty Images


Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

Jan 7, 2021 | 8:11 PM GMT

As Werewolf moves toward the clinic with two lead oncology candidates and a $72 million crossover

Read the full 391 word article

How to gain access

Continue reading with a
two-week free trial.